FINWIRES · TerminalLIVE
FINWIRES

Damora Therapeutics Begins Trial of DMR-001 in ET, Myelofibrosis

By

Damora Therapeutics (DMRA) said Wednesday it initiated a global Phase 1/1b clinical trial of DMR-001 in patients with mutant calreticulin-driven essential thrombocythemia and myelofibrosis.

The open-label, multicenter CLARITY-101 study will evaluate the safety, tolerability and preliminary efficacy of the investigational monoclonal antibody therapy.

The dose-escalation portion will begin with a 100-milligram monthly subcutaneous dose and is designed to identify a recommended dose for further development.

A planned expansion phase will assess DMR-001 in additional patient groups, earlier treatment settings and combinations with other therapies.

Damora expects to report initial trial data beginning in mid-2027, the biotechnology company said.

Price: $30.84, Change: $+0.82, Percent Change: +2.71%

Related Articles

Wire

Zeta Global Swings to Q2 Earnings, Revenue Rises; Shares Drop After Hours

Zeta Global Holdings (ZETA) reported Q2 net income late Tuesday of $8.17 million, swinging from the loss of $12.8 million a year earlier.Revenue in the three months ended June 30 rose to $442.8 million from $308.4 million a year earlier.Analysts surveyed by FactSet expected $420.6 million.The company expects Q3 revenue of $469 million to $472 million, up $10 million at the midpoint from the prior guidance of $461 million.Analysts project $461 million.Zeta boosted full-year guidance to GAAP EPS of $0.09 to $0.11 from the prior forecast of $0.02 to $0.04 on revenue of $1.811 billion to $1.824 billion, up $33 million at the midpoint from the previous projection of $1.785 billion.Analysts expect EPS of $0.04 on revenue of $1.79 billion.Zeta shares fell 6.8% in after-hours trading.

$ZETA
Wire

Voya Financial Q2 Adjusted Earnings, Revenue Fall; Shares Drop After Hours

Voya Financial (VOYA) reported Q2 adjusted net income late Tuesday of $1.51 per diluted share, down from $2.46 a year earlier.Analysts polled by FactSet expected $1.98.Revenue in the three months ended June 30 fell to $1.896 billion from $1.981 billion a year earlier.Analysts expected $1.897 billion.Voya shares fell 3.9% in after-hours trading.

$VOYA
Wire

Toast Q2 Earnings, Revenue Rise; Shares Drop After Hours

Toast (TOST) reported Q2 earnings late Tuesday of $0.26 per diluted share, up from $0.13 a year earlier.Analysts surveyed by FactSet expected $0.20.Revenue in the three months ended June 30 rose to $1.91 billion from $1.55 billion a year earlier.Analysts expected $1.87 billion.Toast shares fell 6.4% in after-hours trading.

$TOST